Leukemia

Selected Abstracts

  1. Schiller GJ, Ho WG, Gajewski JL, Nimer SD, Territo MC, Champlin RE. Intensive induction and consolidation chemotherapy for patients with newly diagnosed acute myelogenous leukemia. Blood 76(10)(Suppl 1):317a, 1990 [Abstract #1258].
  2. Schiller GJ, Nimer SD, Gajewski JL, Ho WG, Lyddane N, Golde DW, Champlin RE. Phase I/II study of etoposide and cytarabine for resistant leukemia. Blood 76(10)(Suppl 1):398a, 1990 [Abstract #1259]
  3. Schiller GJ, Nimer SD, Territo SD, Ho WG, Champlin RE, Gajewski JL. A controlled study comparing bone marrow transplant versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission. Blood 76(10)(Suppl 1):569a, 1990 [Abstract #2265].

Publications

  1. Schiller GJ, Naeim F, Champlin RE. Bone marrow aplasia associated with proliferation of large granular lymphocytes and subsequent transformation to acute lymphoblastic leukemia. American Journal of Hematology 32:153-154, 1989.
  2. Champlin R, Gajewski J, Nimer S, Voliset S, Landaw E, Winston D, Schiller G, Ho W. Post-remission chemotherapy for adults with acute myelogenous leukemia. Improved survival with high-dose cytarabine/daunorubicin consolidation treatment. Journal of Clinical Oncology 8:1199-1206. 1990
  3. Schiller G. Treatment of resistant acute myeloid leukemia. Blood Reviews 5:220-226, 1991.
  4. Schiller GJ, Nimer SD, Territo MC, Ho WG, Champlin RE, Gajewski JL. Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission. Journal of Clinical Oncology, 10:41-46, 1992.
  5. Schiller GJ, Gajewski JL, Nimer SD, Territo M, Ho WG, Lee M, Champlin RE. A randomized study of intermediate vs. conventional-dose cytarabine as intensive induction for acute myelogenous leukemia. British Journal of Hematology 81:170-177, 1992.
  6. Schiller G, Gajewski J, Territo M, Nimer S, Lee M, Belin T, Champlin R. Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Blood 80:2977-2982, 1992.
  7. Aurer I, Sparkes RS, Schiller G, Gale RP. Ph1 chromosome positive acute lymphoblastic leukemia is t(9:22) the initial abnormality? American Journal of Hematology 43:61-62, 1993.
  8. Schiller G, Lee M, Territo M, Gajewski J, Nimer S. A Phase II study of etoposide, ifosfamide and mitoxantrone for the treatment of resistant adult acute lymphoblastic leukemia. American Journal of Hematology 43:195-199, 1993.
  9. Schiller G, Feig S, Territo M, Wolin M, Belin T, Hunt L, Nimer S, Champiln R, Gajewski J. Treatment of advanced acute leukemia with allogeneic bone marrow transplantation from unrelated donors. British Journal of Hematology 88:72-78, 1994.
  10. Schiller G, Gajewski J, Nimer S, Lee M, Ho W, Territo M, Champlin R. Benefit of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia, Leukemia and Lymphoma 15:85-90, 1994.
  11. Wellisch DK, Centeno J, Guzman J, Belin T, Schiller GJ. Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia. A long term follow-up study of quality-of-life measures of survivors. Psychosomatics 37:144-154, 1996.
  12. Schiller G. High-dose consolidation chemotherapy vs. bone marrow transplantation as postremission therapy in adult acute myeloid leukemia. In Emerging Trends in Management of AML. (Monograph) Wiernik PH (Guest Editor), New York: Albert Einstein College of Medicine and Montefiore Medical Center.
  13. Schiller G, Emmanouilides C, Lastrebner MC, Lee M, Naeim F. High-dose cytarabine and recombinant human granulocyte colony-stimulating factor for the treatment of resistant acute myelogenous leukemia. Leukemia and Lymphoma 20:427-434, 1996.
  14. Morosetti R, Grignani F, Liberatore C, Pelicci PG, Schiller GJ, Kizaki M, Bartram CR, Miller CW, Koeffler HP. Infrequent alterations of RARa gene in acute promyelocytic leukemias, myelodysplastic and cell lines. Blood 87:4399-4403, 1996.
  15. Schiller GJ. Postremission therapy of acute myeloid leukemia in older adults. [From Proceedings of Advances and Controversies in Induction Therapy and Treatment of Older Adults with AML] Leukemia 10:(S18-S20), 1996.
  16. Schiller G, emmanouilides C, Iastrebner MC, Lee M, Naeim R.: High-dose cytarabine and recombinant human granulocyte colony-stimulating factor for the tratment of resistant acute myelogenous leukemia. Leukemia and Lymphoma 20:427-434, 1996.
  17. Morosett R, Grignani F, Liberatore C, Pelicci PG, Schiller GJ, Kizaki M, Bartram CR, Miller CW, Koeffler HP. Infrequent alterations of the RAR-alpha gene in acute myelogenous leukemias, retinoic acid-resistant acute promyelocytic leukemias, myelodysplastic syndromes and cell lines. Blood 87:4399-4403, 1996.
  18. Mori N, Morosetti R, Lee S., Spira S, Ben-Yehuda D., Schiller G, Landolfi R., Mizoguchi Hl, Koeffler H.P. Allelotype analysis in the evolution of chronic myelocytic leukemia. Blood 90:2010-2014, 1997.
  19. Schiller G, Lee M. Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for older patients with acute myelogenous leukemia. Leukemia and Lymphoma 25:111-120, 1997.
  20. Schiller G, Lee M, Miller T., Lill M., Mittal-Henkle A., Paquette R., Sawyers C., Territo M. Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy or adults with acute myelogenous leukemia in first remission. Leukemia (in press)
  21. Schiller G, Wong S, Lowe T, Snead G, Paquette R, Sawyers C, Wolin M, Kunkel L, Ting L, Li G, Territo M. Transplantation Of Interleukin 2-Mobilized Autologous Peripheral Blood Progenitor Cells For Adults With Acute Myelogenous Leukemia In First Complete Remission. Leukemia 15: 757-763, 2001.
  22. Schiller G, Lee M, Paquette R, Sawyers C, Khoubian F, Territo M. Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with secondary acute myelogenous leukemia in first remission. Leukemia and Lymphoma 33(5-6): 475-484; 1999.
  23. Schiller GJ. Treatment of Resistant Disease. Leukemia 12(s1):s20-s24, 1998.
  24. Davies SM, Ramsay NKC, Klein JP, Weisdorf DJ, Bolwell B, Cahn JY, Camitta BM, Gale RP, Giralt S, Heilmann C, Henslee-Downey J, Herzig RH, Hutchinson R, Keating A, Lazarus HM, Milone GA, Neudorf S, Powles RL, Prentice G, Schiller G, Socié G, Vowels M, Wiley J, Yeager A, Horowitz M. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. Journal of Clinical Oncology 18:340-347; 2000.
  25. Dorr R, Karanes C, Spier C, Grogan T, Greer J, Moore M, Weinberger J, Schiller G, Pearce T, Litchman M, Dalton W, Roe D, List AF. Phase I/II study of P-Glycoprotein modulator PSC-833 in patients with acute myeloid leukemia. Journal of Clinical Oncology 19: 1589-99, 2001.
  26. Schiller G, Wong S, Lowe T, Snead G, Paquette R, Sawyers C, Wolin M, Kunkel L, Ting L, Li G, Territo M. Transplantation Of Interleukin 2-Mobilized Autologous Peripheral Blood Progenitor Cells For Adults With Acute Myelogenous Leukemia In First Complete Remission. Leukemia 15: 757-763; 2001.
  27. Paquette R, Hsu N, Said J, Mansoor M, Rao N, Schiller G, Sawyers C, Glaspy J. Interferon-a induces dendritic cell differentiation of CML mononuclear cells in vitro and in Vivo. Leukemia 16: 1484-1489; 2002.
  28. Schiller G. Myelodysplasia- therapeutic response to novel therapy and the need for new diagnostic groups. Leukemia 17: 1183-1185; 2003.
  29. Lin MZ, Teitell MA, Schiller GJ. The evolution of antibodies into versatile tumor-targeting agents. Clinical Cancer Review Clin Cancer Res. 11(1):129-38; 2005.
  30. Collisson E, Lashkari A, Paquette R, Emmanouilides C, Ting L, Territo M, Schiller G. Long-term follow-up of transplantation of autologous peripheral blood progenitor cells for adults with acute myelogenous leukemia in first remission. Leukemia 17: 2183-2188; 2005.
  31. Schiller GJ. Is Favorable Risk AML Really Favorable? Leukemia (Leukemia, In Press)
  32. Catenacci D V-T, Schiller GJ. Myelodysplasic syndromes- A comprehensive review (Blood Reviews, In Press)
  33. Emmanouilides C, Colovos C, Pinter-Brown L, Hernandez L, Schiller G, Territo M, Rosen P. Pilot study of fixed infusion rate gemcitabine, with cisplatin and dexamethasone in patients with relapsed and refractory lymphoma. Clinical Lymphoma 5: 45-49; 2004.
  34. Lashkari A, Lowe T, Collisson E, Paquette R, Emmanouilides C, Territo M, Schiller G. Long-Term Outcome of Autologous Transplantation of Peripheral Blood Progenitor Cells as Post-Remission Management of Patients age 60 years and Older with Acute Myelogenous Leukemia (Biology of Blood and Marrow Transplantation, In Press)
  35. Schiller GJ, Slack J, Hainsworth JD, Mason J, Saleh M, Rizzieri D, Douer D, List AF Phase II Multicenter Study of Arsenic Trioxide in Patients With Myelodysplastic Syndromes. J Clin Oncol. 2006 May 1; [Epub ahead of print]
  36. Lashkari A, Lowe T, Collisson E, Paquette R, Emmanouilides C, Territo M, Schiller G. Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of patients > or = 60 years with acute myelogenous leukemia. Biol Blood Marrow Transplant. 2006 Apr;12(4):466-71
  37. Tallman MS, Perez WS, Lazarus HM, Gale RP, Maziarz RT, Rowe JM, Marks DI, Cahn JY, Bashey A, Bishop MR, Christiansen N, Frankel SR, Garcia JJ, Ilhan O, Laughlin MJ, Liesveld J, Linker C, Litzow MR, Luger S, McCarthy PL, Milone GA, Pavlovsky S, Phillips GL, Russell JA, Saez RA, Schiller G, Sierra J, Weiner RS, Zander AR, Zhang MJ, Keating A, Weisdorf DJ, Horowitz MM. Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant. 2006 Feb;12(2):204-16.

Selected Publications

  1. Schiller G, Gajewski J, Territo M, Nimer S, Lee M, Belin T, Champlin R. Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Blood 80: 2977-2982, 1992.
  2. Schiller GJ, Gajewski JL, Nimer SD, Territo M, Ho WG, Lee M, Champlin RE. A randomized study of intermediate vs. conventional-dose cytarabine as intensive induction for acute myelogenous leukemia. British Journal of Hematology 81: 170-177, 1992.
  3. Schiller G, Lee M: Long-Term Outcome of High-Dose Cytarabine-Based Consolidation Chemotherapy for Older Patients with Acute Myelogenous Leukemia. Leukemia and Lymphoma 25: 111-119, 1997.
  4. Schiller G, Lee M, Miller T, Lill M, Mittal-Henkle A, Paquette R, Sawyers C, Territo M: Transplantation of Autologous Peripheral Blood Progenitor Cells Procured after High-Dose Cytarabine-Based Consolidation Chemotherapy for Adults with Acute Myelogenous Leukemia in First Remission. Leukemia (in press).
  5. Wellisch DK, Centeno J, Guzman J, Belin T, Schiller GJ: Bone Marrow Transplantation vs. High-Dose Cytarabine-Based Consolidation Chemotherapy for Adults with Acute Myelogenous Leukemia- A Long-Term Follow-Up Study of Quality-of-Life Measures of Survivors. Psychosomatics 37: 144-154, 1996.
  6. Schiller G, Wong S, Lowe T, Snead G, Paquette R, Sawyers C, Wolin M, Kunkel L, Ting L, Li G, Territo M: Transplantation of IL-2-mobilized autologous peripheral blood progenitor cells for adults with acute myelogenous leukemia in first remission. Leukemia 15: 757-763, 2001.

Return to Index / Studies at UCLA / Book Chapters / Lymphoma

Stem Cell & Bone Marrow Transplantation / Multiple Myeloma / Cancer - Breast & Lung

Gary Schiller, M.D., F.A.C.P. / Coll Design © 1996 All rights reserved.